FRNM
Freenome, Inc.
Set alert
- YTD
- -4.22%
- 1 year
- +16.64%
- Open
- 12.64
- Prev close
- 12.86
- Mkt cap
- 1.34B
- Vol
- 651.14K
- Avg vol
- 842.36K
- EPS
- -2.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.59
- High
- 12.71
- Forward P/E
- -5.19
- Beta
- 0.45
- Short ratio
- 4.91
- Inst. own
- 42.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2026
- 50-d avg
- 14.76
- 200-d avg
- 12.52
- 1y target
- 18.00
News
1 week ago fool.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest added to three existing positions on Monday, all of them down sharply from recent highs.
-
1 week ago benzinga.com
Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at…
1 week ago globenewswire.com
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at…
2 weeks ago globenewswire.com
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to…
2 weeks ago globenewswire.com
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
- Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention - - Overall detection of…
3 weeks ago benzinga.com
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
1 month ago seekingalpha.com
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target the vast unscreened colorectal market. FRNM's SimpleScreen CRC, now out-licensed to Abbott, offers a…
2 months ago benzinga.com
Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
U.S. stocks mixed, Nasdaq falls 0.1%. Gap Inc shares rise 15.2% on strong earnings and raised guidance. Other big gainers include Elastic NV, Solstice Advanced Materials Inc, and Pagerduty Inc.
-
2 months ago benzinga.com
Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21
Guggenheim analyst Subbu Nambi initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $21.
-
2 months ago benzinga.com
Frenome Files Prospectus Related To The Offer And Sale From Time To Time By The Selling Securityholders Of Up To 75,188,742 Shares Of Common Stock
https://www.sec.gov/ix?doc=/Archives/edgar/data/0002017526/000114036126033585/ny20080283x1_s1.htm
-
2 months ago benzinga.com
TD Cowen Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
TD Cowen analyst Dan Brennan initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $17.
-
2 months ago benzinga.com
Jefferies Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
Jefferies analyst Tycho Peterson initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $17.
-
2 months ago benzinga.com
BTIG Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
BTIG analyst Mark Massaro initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $17.
-
2 months ago benzinga.com
Leerink Partners Initiates Coverage On Freenome with Outperform Rating, Announces Price Target of $18
Leerink Partners analyst Puneet Souda initiates coverage on Freenome (NASDAQ:FRNM) with a Outperform rating and announces Price Target of $18.
-
2 months ago benzinga.com
Freenome Receives FDA Breakthrough Device Designation For Its Investigational Lung Cancer Screening Test SimpleScreen Lung
The designation applies to the proposed use of SimpleScreen Lung in adults ages 50 to 80 who have at least a 20 pack-year smoking history and are not currently participating in guideline-recommended…
2 months ago globenewswire.com
FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and…
3 months ago reuters.com
FDA approves Freenome's blood test for colorectal cancer screening
The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the U.S. this fall, the companies said on…
-
3 months ago benzinga.com
Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment
Screening is for colorectal cancer (CRC) in adults 45 and older who are at average risk for the disease. Abbott will exclusively commercialize the test in the U.S. this fall, expanding its CRC…
3 months ago globenewswire.com
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader…
3 months ago globenewswire.com
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to Freenome totaled more than $300 million through a…